FATE THERAPEUTICS INC
FATENasdaq
$2.78
↑ +1.8%Jul 17 close · end-of-day
Price
1Y↑ +146.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$333.7M
Enterprise Value
$158.9M
P/E
—
P/S
52.8
P/B
1.9
EV/EBITDA
—
PEG
—
FCF Yield
-32.4%
Dividend Yield
—
Revenue (TTM)
$6.3M
Net Income (TTM)
-$129.9M
Free Cash Flow (TTM)
-$108.1M
Gross Margin
—
Operating Margin
-2207.5%
Net Margin
-2056.8%
ROE
-72.3%
ROIC
-2254.8%
Debt / Equity
—
Net Cash
$174.8M
Return 1Y
+141.7%
Company profile
Fate Therapeutics, Inc. develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cells product candidates.
- CEO
- J. Scott Wolchko
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 550
- Headquarters
- California
- Website
- fatetherapeutics.com
Management & directors
- Tahl CindySee Remarks
- Valamehr BahramPresident and CEO
- Adawi KamalChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
FATE Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$1.3M↓ -20.3%
Diluted EPS-$0.26↓ -18.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $31.4M | $55.8M | $96.3M | $63.5M | $13.6M | $6.6M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$128.1M | -$217.0M | -$308.4M | -$190.5M | -$210.3M | -$147.7M |
| Net income | -$173.4M | -$212.2M | -$281.7M | -$160.9M | -$186.3M | -$136.3M |
| Diluted EPS | -$2.10 | -$2.24 | -$2.91 | -$1.64 | -$1.64 | -$1.15 |
| Operating cash flow | -$39.2M | -$162.9M | -$248.2M | -$132.3M | -$122.9M | -$106.1M |
| Free cash flow | -$44.2M | -$213.6M | -$283.8M | -$138.4M | -$123.6M | -$112.0M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -407.5% | -388.6% | -320.2% | -299.9% | -1542.6% | -2222.4% |
| Net margin | -551.6% | -379.9% | -292.5% | -253.3% | -1366.5% | -2051.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.8M | $3.1M | $1.9M | $1.6M | $1.9M | $1.7M | $1.4M | $1.3M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$45.1M | -$52.4M | -$61.7M | -$41.3M | -$37.0M | -$34.7M | -$34.7M | -$33.0M |
| Net income | -$38.4M | -$47.7M | -$52.2M | -$37.6M | -$34.1M | -$32.3M | -$32.4M | -$31.2M |
| Diluted EPS | -$0.33 | -$0.40 | -$0.44 | -$0.32 | -$0.29 | -$0.27 | -$0.27 | -$0.26 |
| Operating cash flow | -$32.3M | -$29.4M | -$27.8M | -$33.8M | -$24.6M | -$24.4M | -$23.3M | -$30.8M |
| Free cash flow | -$32.4M | -$29.9M | -$27.9M | -$35.0M | -$25.9M | -$26.6M | -$24.5M | -$31.1M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -665.7% | -1703.9% | -3319.8% | -2534.1% | -1938.5% | -1995.1% | -2536.2% | -2540.4% |
| Net margin | -567.4% | -1551.0% | -2803.9% | -2309.5% | -1786.6% | -1852.4% | -2364.8% | -2402.8% |
Company news
Jul 9, 2026
- 10d agoFATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trialsstocktwits.com
- 11d agoSector Update: Healthcare Stocks Softer Late Afternoonfinance.yahoo.com
- 11d agoFate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidatefinance.yahoo.com
Jul 1, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-20 | Valamehr Bahram· President and CEO | Sale | 28,946 | $1.88 | $54,482.16 | filing |
| 2026-05-20 | TAHL CINDY· See Remarks | Sale | 25,590 | $1.88 | $48,083.61 | filing |
| 2026-05-06 | TAHL CINDY· See Remarks | Option exercise | 122,220 | $1.32 | $161,330.40 | filing |
| 2026-05-06 | TAHL CINDY· See Remarks | Option exercise | 44,444 | $1.05 | $46,666.20 | filing |
| 2026-05-05 | EPSTEIN ROBERT S | Option exercise | 25,000 | $1.69 | $42,250.00 | filing |
| 2026-05-05 | RASTETTER WILLIAM H | Option exercise | 25,000 | $1.69 | $42,250.00 | filing |
| 2026-04-20 | Redmile Group, LLC | J | 8,977,624 | $0.00 | $0.00 | filing |
| 2026-04-20 | Redmile Group, LLC | J | 8,977,624 | $0.00 | $0.00 | filing |
| 2026-01-15 | TAHL CINDY· See Remarks | Award | 100,000 | $0.00 | $0.00 | filing |
| 2026-01-15 | Adawi Kamal· Chief Financial Officer | Award | 25,000 | $0.00 | $0.00 | filing |
| 2026-01-15 | Valamehr Bahram· President and CEO | Award | 335,000 | $0.00 | $0.00 | filing |
| 2026-01-09 | TAHL CINDY· See Remarks | Sale | 10,589 | $1.06 | $11,275.17 | filing |
| 2026-01-09 | Valamehr Bahram· President and CEO | Sale | 5,190 | $1.07 | $5,557.45 | filing |
| 2025-10-20 | Adawi Kamal· Chief Financial Officer | Award | 75,000 | $0.00 | $0.00 | filing |
| 2025-08-04 | Valamehr Bahram· President and CEO | Sale | 14,466 | $1.06 | $15,396.16 | filing |
| 2025-08-04 | TAHL CINDY· See Remarks | Sale | 9,037 | $1.06 | $9,572.89 | filing |
Latest 16 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.